28
Participants
Start Date
March 31, 2006
Primary Completion Date
May 31, 2008
Study Completion Date
May 31, 2008
Bevacizumab and Sunitinib
On Cycle 1, Day 0, patients will begin treatment with bevacizumab. Sunitinib will begin on Day 1. The starting dose for sunitinib will be 25mg orally daily. sunitinib will be given in a four weeks on-two weeks off schedule. Bevacizumab will begin on Day 0 and will be administered every two weeks at 10mg/kg. A cycle of therapy is 6 weeks. The sunitinib dose escalation portion of the trial will be performed to determine the MTD of sunitinib given in combination with bevacizumab. Once the MTD has been determined, 10 additional patients will be treated at the MTD of sunitinib in combination with bevacizumab.
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York
Memorial Sloan Kettering Cancer Center
OTHER